A large recap points to the acceleration of AI infrastructure investment in drug discovery, highlighting continued billion-dollar funding into end-to-end AI platforms. The piece emphasizes that investors are backing systems built around models and compute rather than single-asset bets and notes major platform partnerships that embed AI workflows into pharma R&D. Within the coverage, Isomorphic Labs is cited as an example of the approach, including its Drug Design Engine for predicting cryptic binding pockets and partnerships intended to scale discovery across modalities. The report frames the current push as shifting target identification and design toward previously inaccessible biology. For biotech leadership teams, the practical consequence is that AI-enabled discovery capabilities are increasingly competing on platform throughput, integration into existing discovery pipelines, and ability to deliver candidate-level differentiation early enough for conventional development teams to execute.